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interfering RNA; SOCS = suppressor of cytokine signaling; STAT = signal transduction and activators of transcription; Th = T helper; TLR = Toll-
like receptor; TNF = tumor necrosis factor.
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Abstract
Immune and inflammatory systems are controlled by multiple
cytokines, including interleukins and interferons. Many of these
cytokines exert their biological functions through JAKs (Janus
tyrosine kinases) and STAT (signal transduction and activators of
transcription) transcription factors. CIS (cytokine-inducible SH2
(Src homology 2) protein) and SOCS (suppressor of cytokine
signaling) are a family of intracellular proteins, several of which
have emerged as key physiological regulators of cytokine-mediated
homeostasis, including innate and adaptive immunity. In this review
we focus on the molecular mechanism of the action of CIS/SOCS
family proteins and their roles in immune regulation and
inflammatory diseases including rheumatoid arthritis.
Introduction
Cytokines regulate many physiological responses and
homeostasis, influencing the survival, proliferation, differen-
tiation and functional activity of cells of the immune system,
as well as those of most other organ systems [1]. Cytokines,
including interleukins, IFNs and hemopoietins, activate the
Janus kinases (JAK1, JAK2, JAK3 and Tyk2) that associate
with their cognate receptors. Activated JAKs phosphorylate
the receptor cytoplasmic domains that create docking sites
for Src homology 2 (SH2)-containing signaling proteins.
Among the substrates of tyrosine phosphorylation are
members of the signal transducers and activators of
transcription family of proteins (STATs) [2,3]. For example,
IFN-γ uses JAK1 and JAK2, which activate mainly STAT1,
whereas IL-6 binding to the IL-6 receptor α chain and gp130
activates primarily JAK1 and STAT3. Interestingly, the anti-
inflammatory cytokine IL-10 also activates STAT3. STAT4
and STAT6 are essential for T helper (Th)1 and Th2
development, Because these are activated by IL-12 and IL-4,
respectively. STAT5 is activated by many cytokines including
IL-2, IL-7, erythropoietin and growth hormones. These are
summarized in Fig. 1.
It has been recognized that sustained and/or excessive action
of cytokines can be harmful to organisms. Accordingly,
several mechanisms have been reported to modulate
cytokine signaling to prevent this overaction of cytokines. For
example, soluble forms of cytokine receptors that lack
intracellular domains can inhibit the action of cytokines by
simple competition for cytokine binding. Endocytosis of
receptors and proteasomal degradation of signaling
molecules after initial ligand stimulation is thought to have a
role in preventing continuous cytokine signaling. In addition,
several molecules that actively function as negative regulators
of cytokine signaling, including SH2-containing phosphatase
SHP-1, protein tyrosine phosphatase 1B (PTP1B), CD45
and T cell protein tyrosine phosphatase (TCPTP) [4] have
also been reported to inhibit cytokine signaling as JAK
phosphatases. The PIAS (protein inhibitors of activated
STATs) family of proteins can inhibit the function of STATs by
binding directly [5]. Moreover, recently accumulating
evidence suggests that another family of proteins, suppressor
of cytokine signaling (SOCS) proteins, is an important
negative regulator for cytokine signaling [6,7].
CIS/SOCS family: structure and action
mechanism
SOCS and cytokine-inducible SH2 protein (CIS) are a family
of intracellular proteins, several of which have been shown to
regulate the responses of immune cells to cytokines [6–10].
The discovery of the SOCS proteins seemed to have defined
an important mechanism for the negative regulation of the
cytokine–JAK–STAT pathway; however, recent studies using
gene-disrupted (knockout; KO) mice have unexpectedly
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revealed profound roles of SOCS proteins in many
immunological and pathological processes.
There are eight CIS/SOCS family proteins: CIS, SOCS1,
SOCS2, SOCS3, SOCS4, SOCS5, SOCS6 and SOCS7;
each has a central SH2 domain, an amino-terminal domain of
variable length and sequence, and a carboxy-terminal 40-
amino-acid module known as the SOCS box (Fig. 2). The
SOCS box has also been found in ASBs (ankyrin repeat-
containing proteins with a SOCS box), SSBs (SPRY domain-
containing proteins with a SOCS box) and WSBs (WD40
repeat-containing proteins with a SOCS box), as well as other
miscellaneous proteins. The SOCS-family members best
characterized so far are CIS, SOCS1, SOCS2 and SOCS3.
CIS was the first member identified in this family [11]. CIS and
SOCS2 bind to phosphorylated tyrosine residues on activated
(phosphorylated) cytokine receptors. Competition or steric
hindrance for binding sites that are used to recruit and activate
STATs (especially STAT5) has been proposed as the
mechanism by which CIS and SOCS2 inhibit cytokine
signaling [11,12]. CIS is induced by cytokines that activate
STAT5 and bind to receptors that activate STAT5, namely
erythropoietin, IL-2, IL-3, prolactin and growth hormone (GH)
[11]. From an analysis of KO mice, SOCS2 has been shown
to be a relatively specific negative regulator of GH–STAT5
[13,14]. SOCS5 has been shown to inhibit IL-4 signaling by
interacting with the IL-4 receptor and inhibiting JAK1 binding
to the receptor [15]. As mentioned below, receptor-
CIS/SOCS complex is degraded by the ubiquitin–proteasome
system, which could be an important inhibitory mechanism.
Both SOCS1 and SOCS3 can inhibit JAK tyrosine kinase
activity because they have the kinase inhibitory region (KIR) in
Figure 1
The JAK/STAT (Janus family kinase/signal transduction and activators of transcription) pathway. EPO, erythropoietin; G-CSF, granulocyte colony-
stimulating factor; IFN, interferon; IL, interleukin; JAK, Janus kinase; OSM, oncostatin M; STAT, signal transduction and activators of transcription;
Th, T helper.102
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their N-terminal domain, which is proposed to function as a
pseudosubstrate [16] (Fig. 3). A three-dimensional structural
model of the SOCS1/JAK2 complex has been proposed
[17]. Whereas SOCS1 binds directly to the activation loop of
JAKs through its SH2 domain, the SOCS3 SH2 domain
binds the cytokine receptor (Fig. 3). The SOCS3 SH2
domain has been shown to bind to Tyr757 of gp130, Tyr985
of the leptin receptor and Tyr401 of the erythropoietin
receptor, Tyr729 of the granulocyte colony-stimulating factor
(G-CSF) receptor, Tyr800 of the IL-12 receptor and Tyr985
of the leptin receptor, most being the same binding sites for
protein tyrosine phosphatase 2 (SHP-2) [18–22]. De Souza
and colleagues [23] have mapped the phosphopeptide
binding preferences of the SH2 domain from SOCS3 by
using degenerate phosphopeptide libraries. They found that
the consensus ligand-binding motif for SOCS3 was pTyr-
(Ser/Ala/Val/Tyr/Phe)-hydrophobic-(Val/Ile/Leu)-hydrophobic-
(His/Val/Ile/Tyr). The sequence around Tyr759 of gp130
(-pTyr-Ser-Thr-Val-Val-His-) almost completely matches this
motif. Although SOCS3 binds with a much higher affinity to a
gp130 phosphopeptide around Tyr759 than to phospho-
peptides derived from other receptors, such as leptin and
erythropoietin receptors, multiple SOCS3-binding sites are
predicted to exist in these receptors, which might
compensate for weaker binding to individual sites.
The function of the SOCS box is the recruitment of the
ubiquitin-transferase system. The SOCS box interacts with
Elongins B and C, Cullin-5 or Cullin-2, Rbx-1 and E2
[24–26]. Thus, CIS/SOCS family proteins, as well as other
SOCS-box-containing molecules, probably function as E3
ubiquitin ligases and mediate the degradation of proteins
associated through their N-terminal regions. SOCS proteins
therefore seem to combine specific inhibition (that is, kinase
inhibition by KIR) and a generic mechanism of targeting
interacting proteins for proteasomal degradation. The
importance of the SOCS box has been recognized from the
following evidence: the SOCS box of SOCS1 is necessary
for the suppression of the oncogenic activity of TEL-JAK2 by
SOCS1 [27,28] as well as for the degradation of wild-type
activated JAK2 [29], and mice that were genetically modified
to lack only the SOCS box of SOCS1 exhibited inflammatory
diseases similar to complete SOCS1-deficient mice with
slower onsets [30]. SOCS1 is also suggested to be involved
in the degradation of Vav [31] and in the ubiquitination and
degradation of a papilloma virus oncoprotein, E7 [32].
SOCS1 and SOCS3 have also been shown to downregulate
insulin signaling by inducing the degradation of insulin
receptor substrate (IRS)-1 and IRS-2 [33,34]. However, the
SOCS box is also known to be important for stabilization
and/or degradation of the SOCS1 and SOCS3 proteins
themselves [24]. The role of the SOCS box in the function of
each of the SOCS proteins remains to be investigated further.
Physiological function of CIS/SOCS
molecules defined by gene targeting
CIS1
CIS-transgenic mice exhibited growth retardation, impaired
mammary gland development and reduced numbers of
natural killer (NK) and NK T cells. These phenotypes in CIS-
transgenic mice are remarkably similar to those observed in
STAT5a KO and/or STAT5b KO mice [35], which is
Figure 2
Structures of suppressor of cytokine signaling (SOCS) family molecules. CIS, Src homology 2 (SH2)-containing protein; EPO, erythropoietin; JAB,
JAK (Janus family kinase)-binding protein; KIR, kinase inhibitory region; NAP4, Nck/Ash-binding protein 4; SSI-1, STAT (signal transducer and
activator of transcription)-induced STAT inhibitor-1.103
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consistent with CIS having a specific role in the regulation of
STAT5-mediated cytokine responses. Several reviews have
mentioned that no obvious phenotype is observed in CIS KO
mice but without showing any data. However, we have
preliminary data suggesting that CIS is an important negative
regulator of hematopoietic growth factors, including erythro-
poietin, IL-3 and thrombopoietin (A Yoshimura, unpublished
data). These are consistent with our initial proposal that CIS
is a negative regulator of STAT5 [11].
SOCS1
Although SOCS1 KO mice are normal at birth, they exhibit
stunted growth and die within 3 weeks with a syndrome
characterized by severe lymphopenia, activation of peripheral
T cells, fatty degeneration and necrosis of the liver, and
macrophage infiltration of major organs (acute SOCS1–/–
disease) [36,37]. The neonatal defects exhibited by SOCS1–/–
mice seem to occur primarily as a result of unbridled IFN-γ
signaling, because SOCS1–/– mice that also lack the IFN-γ
gene or the IFN-γ receptor gene do not die neonatally
[38–40]. Constitutive activation of STAT1 and constitutive
expression of IFN-γ-inducible genes were observed in
SOCS1 KO mice. These data strongly suggest that the
excess IFN-γ is derived from the abnormally activated T cells
in SOCS1–/– mice. However, SOCS1 also has important
regulatory functions in IFN-γ-independent inflammatory
diseases; these are discussed later.
SOCS2
SOCS2 is known to bind to GH receptors and to inhibit the
activation of STAT5b induced by GH. SOCS2-deficient mice
at 12 weeks after birth exhibited a 30 to 40% increase in
body weight compared with control mice; they also showed
hypertrophy of the liver and other visceral organs related to
the increase in weight [14]. Growth promotion by GH is
dependent on the induction of insulin-like growth factor-1
(IGF-1) by GH, whereas SOCS2-deficient mice do not
exhibit an increase in serum IGF-1. Expression of SOCS2 is
not directly induced by IGF-1 but is directly induced by GH.
In SOCS2-deficient mice GH-induced STAT5 activation, but
not IGF-1 signaling, is mildly enhanced [13]. Furthermore,
SOCS2–/–STAT5b–/– double KO mice showed normal
growth [13]. These data suggest that the action of SOCS2 is
in the regulation of the GH signaling pathway.
SOCS3
SOCS3 KO mice die by placental function defects during the
embryonic stage of development [41,42]. Deletion of SOCS3
causes an embryonic lethality that can be saved by a
tetraploid rescue approach, which demonstrates an essential
Figure 3
The molecular mechanism by which suppressor of cytokine signaling 1 (SOCS1) and SOCS3 negatively regulate Janus kinase (JAK) activation.
SOCS1 binds to the JAKs and inhibits catalytic activity; SOCS3 binds to JAK-proximal sites on cytokine receptors and inhibits JAK activity through
KIR (kinase inhibitory region). These complexes may be degraded by ubiquitination and proteasomal degradation recruited through the SOCS box.104
role in placental development and a non-essential role in
embryo development. Rescued SOCS3-deficient mice show
a prenatal lethality with cardiac hypertrophy, suggesting that
SOCS3 is essential for regulating LIF receptors or gp130
signaling [42]. Conditional KO mice studies demonstrated
that SOCS3 is an important negative regulator of IL-6
[43–45] and G-CSF [46,47]. Mice in which the SOCS3
gene was deleted in all hematopoietic cells developed
neutrophilia and a spectrum of inflammatory pathologies [47].
When stimulated with G-CSF in vitro, SOCS3-deficient cells
of the neutrophilic granulocyte lineage exhibited prolonged
STAT3 activation and enhanced cellular responses to G-CSF
[46,47]. SOCS3-deficient mice injected with G-CSF
displayed enhanced neutrophilia, progenitor cell mobilization
and splenomegaly, but unexpectedly also developed
inflammatory neutrophil infiltration into multiple tissues and
consequent hindleg paresis [47]. Interestingly, conditional
STAT3 deletion in neutrophils also exhibited hyper-responses
to G-CSF [48], suggesting that a major role of STAT3 in
neutrophils is the induction of SOCS3. It is probable that the
ERK (extracellular signal-related kinase) pathway induced by
G-CSF has a major function in the proliferation and
differentiation of neutrophils.
Recently, the essential roles of SOCS3 in endocrine systems
have also been clarified. Administration of leptin to neural cell-
specific SOCS3 conditional KO mice greatly reduces their
food intake and causes enhanced body weight loss
compared with wild-type mice, indicating that SOCS3 in the
brain negatively regulates leptin signaling [49]. Similar
findings were observed in SOCS3 heterozygous mice [50].
Moreover, Socs3-deficient mice were resistant to weight gain
and hyperleptinemia induced by a high-fat diet, and sensitivity
to insulin was retained. These data indicate that SOCS3 is a
key regulator of diet-induced leptin and also insulin resistance
[49]. In addition, SOCS3-deficient adipocytes generated
from SOCS3 KO fibroblasts are significantly protected from
tumor necrosis factor (TNF)-α-induced insulin resistance,
mainly due to reduced proteasomal degradation of IRS
proteins by TNF-α, suggesting that SOCS3 is an important
mediator of insulin resistance in vivo [51]. Taken together,
these results indicate that SOCS3 can be a potential
therapeutic target for many prevalent human metabolic
disorders such as obesity and diabetes.
SOCS5
A study with SOCS5 transgenic mice suggested that
SOCS5 inhibits Th2 differentiation by inhibiting IL-4 signaling
[14]. SOCS5 is expressed preferentially in Th1 cells and
SOCS5 can interact with the IL-4 receptor in the absence of
tyrosine phosphorylation. This interaction of SOCS5 with the
IL-4 receptor is likely to cause the reduction in IL-4-induced
activation of STAT6 and thus to regulate Th2 polarization. In
line with this finding, T cells from SOCS5 transgenic mice
also exhibit reduced Th2 polarization. However, a recent
analysis of SOCS5 KO mice failed to confirm the roles of
SOCS5 in lymphocyte function [52]. CD4+ T cells in SOCS5
KO mice showed a normal Th1/Th2 response both in vitro
and in vivo. The conflicting findings in SOCS5 KO mice may
be explained by SOCS5 being compensated for by other
SOCS proteins such as SOCS4, because SOCS4 shares
significant homology with SOCS5. Further analyses including
those of SOCS4/SOCS5 double KO mice may be required
to address the function of SOCS5 in vivo.
A  Drosophila SOCS protein that is highly homologous to
mammalian SOCS5 was cloned and named SOCS36E.
Interestingly, ectopic expression of SOCS36E in transgenic
flies results in phenotypes resembling those of flies defective
in JAK/STAT or epidermal growth factor signaling [53]. This
result could imply that mammalian SOCS5 is also involved in
the regulation of JAK/STAT and/or epidermal growth factor
signaling in mammals, but future studies are required to
address this issue.
SOCS6
Mice lacking SOCS6 have been generated and develop
normally with the exception of a 10% reduction in weight
compared with wild-type littermates [54]. SOCS6 mRNA was
expressed ubiquitously in murine tissues [54]. SOCS6 and
SOCS7 SH2 domains interacted with a protein complex
consisting of IRS-4, IRS-2 and the p85 regulatory subunit of
phosphoinositide 3-kinase. However, there is no evidence so
far to suggest that SOCS6 might be involved in the
degradation of proteins [54].
SOCS7
SOCS7 is highly expressed in the brain. SOCS7–/– mice
were 7 to 10% smaller than their wild-type littermates, and
within 15 weeks of age about 50% of the SOCS7-deficient
mice died as a result of hydrocephalus that was characterized
by cranial distortion, dilation of the ventricular system,
reduced thickness of the cerebral cortex and disorganization
of the subcommissural organ [55]. Thus, SOCS7 is important
in the functioning of neuronal cells.
SOCS1 and innate immunity
SOCS1 deficiency in the hematopoietic compartment is
thought to be sufficient to cause a SOCS1–/– disease,
because transfer of SOCS1–/– bone marrow into irradiated
JAK3-deficient recipients results in premature lethality
[38,56]. SOCS1–/– rag-2–/– mice do not die prematurely
[38], and SOCS1–/– NK T cells have been reported to be
more numerous than normal in the liver and to be cytotoxic for
syngenic liver cells [57]. T and/or NK T cells have therefore
been suggested to have essential functions in SOCS1–/–
diseases. However, mice lacking the SOCS1 gene,
specifically in T and NK T cells, did not develop any of the
inflammatory pathologies or neonatal death found in
SOCS1–/– mice [58]. This indicates that other hematopoietic
cells in addition to T and NK T cells are deeply involved in
SOCS1–/– inflammatory diseases. Strong candidates are
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antigen-presenting cells including macrophages and
dendritic cells (DCs).
Bacterial lipopolysaccharide (LPS) triggers innate immune
responses through Toll-like receptor 4 (TLR4). Other
bacterial pathogens including proteoglycans and CpG-DNA
also activate other TLR-family receptors. Regulation of TLR
signaling is a key step in inflammation, septic shock and
innate/adaptive immunity. SOCS1 and SOCS3 were found
to be induced by LPS or CpG-DNA stimulation in
macrophages [59–61]. SOCS1 has been implicated in hypo-
responsiveness to cytokines such as IFN-γ after the exposure
of macrophages to LPS [61]. Furthermore, SOCS1-deficient
mice are found to be more sensitive to LPS shock than wild-
type littermates [62,63]. SOCS1–/– mice (before disease
onset), SOCS1+/– mice and IFN-γ–/–SOCS1–/– mice, as well
as STAT1–/–SOCS1–/– mice, have all been shown to be
hyper-responsive to LPS and very sensitive to LPS-induced
lethality. Macrophages from these mice produced increased
levels of the pro-inflammatory cytokines, such as TNF-α and
IL-12, as well as nitric oxide (NO), in response to LPS. One
important mechanism of the suppression of LPS-induced
macrophage activation by SOCS1 is the inhibition of IFN-β
signaling indirectly activated by LPS [64,65]. However, a
direct effect of SOCS1 on the TLR–NF-κB pathway has
been also proposed [62,63]. Ryo and colleagues [66]
showed that direct binding of SOCS1 to the p65 subunit of
NF-κB induces proteasomal degradation of p65, which is one
potential mechanism of TLR signal suppression by SOCS.
Moreover, LPS tolerance was severely impaired in SOCS1–/–
mice and SOCS1-deficient peritoneal macrophages [62,63].
However, Gingras and colleagues [64] did not observe
enhanced LPS responses in SOCS1-deficient bone marrow-
derived macrophages cultured with macrophage colony-
stimulating factor (M-CSF). The nature of bone marrow-
derived macrophages cultured in M-CSF in vitro is different
from that of primary peritoneal macrophages [62–64].
SOCS1-deficient macrophages in tissue may be already
affected by various environmental cytokines. Even so,
SOCS1 is still deeply involved in the regulation of macro-
phage activation through regulating not only the JAK/STAT
pathway but also the TLR–NF-κB pathway (Fig. 4).
SOCS1-deficient DCs are also hyper-activated and may be
involved in the pathology found in SOCS1–/– mice [67]. We
generated mice in which SOCS1 expression was restored in
T and B cells on a SOCS1–/– background (SOCS1–/–
transgenic mice). In these mice, DCs were abnormally
accumulated in the thymus and spleen and produced high
levels of BAFF/BLyS and APRIL, resulting in the aberrant
expansion of B cells and autoreactive antibody production.
SOCS1-deficient DCs efficiently stimulated B cell
proliferation  in vitro and autoantibody production in vivo.
These results indicate that SOCS1 is essential to normal DC
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Figure 4
Regulation of lipopolysaccharide (LPS) signaling by suppressor of cytokine signaling 1 (SOCS1). LPS stimulates NF-κB and the JNK/p38 pathway
through Toll-like receptor (TLR)4/MD2 receptor. IFN-β is rapidly induced through the TRIF/IRF-3 pathway and activates the JAK/STAT1 (Janus
kinase/signal transduction and activators of transcription 1) pathway. SOCS1 is probably induced by STAT1 and NF-κB, and then suppresses
both STAT1 and NF-κB. One possible mechanism of NF-κB suppression is the induction of degradation of the p65 NF-κB subunit.106
functions and to the suppression of systemic autoimmunity
that develops in SOCS1–/– transgenic mice [67].
Furthermore, we speculate that SOCS1–/– DCs are important
in the onset of SOCS1–/– diseases, because SOCS1-
deficient DCs can activate the proliferation not only of B cells
but also of allogenic T cells [67]. We also observed that T
cells produce higher amounts of Th1 cytokines such as IFN-γ
and TNF-α in response to SOCS1–/– DCs than to wild-type
DCs [68]. This nature of SOCS1-deficient DCs can be
applied to anti-tumor immunity, because strong Th1 induction
is believed to be important for DC-mediated vaccination.
Shen and colleagues [69] reported that silencing the SOCS1
gene by using short-interfering-RNA (siRNA) technology in
antigen-presenting DCs strongly enhances antigen-specific
anti-tumor immunity. They showed that DCs transfected with
SOCS1 siRNA were more responsive to LPS or IFN-γ than
were DCs transfected with control siRNA, as indicated by an
enhanced secretion of proinflammatory cytokines such as IL-
6 and TNF-α and by the enhanced phosphorylation of
STAT1, IκB and JNK upon stimulation. Antigen (ovalbumin)
peptide-pulsed SOCS1-siRNA-treated DCs stimulated
ovalbumin-specific cytotoxic T cell proliferation and
functioned more strongly than did control DCs. These data
indicate that SOCS1-deficient DCs can strongly activate
CD4+ (helper) and CD8+ (cytotoxic) T cells.
SOCS3 and innate immunity
IL-6 is a pro-inflammatory cytokine that has a progressive
function in many inflammatory diseases, whereas IL-10 is an
immunoregulatory cytokine that has potent anti-inflammatory
activity. Although the transcription factor STAT3 is essential
for the function of both IL-6 and IL-10 [70], it is not clear how
these two cytokines exhibit such opposite functions.
Recently, we demonstrated that at least in macrophages
SOCS3 is a key regulator of the divergent action of these
two cytokines. In macrophages lacking the SOCS3 gene, or
carrying a mutation of the SOCS3 binding site (Y759F) in
gp130, not only IL-10 but also IL-6 suppressed LPS-induced
TNF-α production [43]. SOCS3 protein was strongly induced
by both IL-6 and IL-10 in the presence of LPS, but selectively
inhibited IL-6 signaling, because SOCS3 bound the IL-6
receptor, gp130 (Y759), but not the IL-10 receptor [43].
These data indicate that SOCS3 selectively blocks IL-6
signaling, interfering with its ability to inhibit LPS signaling
(Fig. 5). Consistent with this is the observation that mice
specifically lacking the SOCS3 gene in macrophages and
neutrophils are resistant to acute inflammation as modeled by
LPS shock. This phenotype is the complete opposite to
macrophages in STAT3 conditional KO mice, which are more
sensitive to LPS shock and produce more TNF-α in response
to LPS [70]. We also found a similar opposite relationship
between STAT3 and SOCS3 on DC activation (Y Matsumura
and A Yoshimura, unpublished data).
Others have shown that IL-6 strongly activates STAT1 and
induces the expression of IFN-responsive genes in SOCS3-
deficient macrophages, implying that IL-6 might mimic the
action of IFNs [44,45]. Interestingly, these reports also
demonstrated that the absence of SOCS3 in macrophages
changes the original function of IL-6. All three studies
therefore indicate that SOCS3 is an important regulator to
maintain a specific biological function on gp130-related
cytokines in vivo. From such an interesting biochemical and
biological function of SOCS3, we might be able to convert
inflammatory cytokine IL-6 to an anti-inflammatory cytokine by
suppressing the expression of SOCS3 in macrophages.
SOCS1 and inflammatory diseases
Given the wide range of immunoregulatory functions, SOCS1
might be implicated in the pathology of inflammatory
diseases. In a murine model of autoimmune arthritis, joint
inflammation and destruction was significantly enhanced in
mice lacking SOCS1 [71,72]. Blood CD4+ T cells from
patients with rheumatoid arthritis (RA) contained higher levels
of SOCS1 but lower levels of SOCS3 mRNA than control
CD4+ T cells, as determined by real-time polymerase chain
reaction [73]. This higher expression of SOCS1 in T cells
might explain the imbalance of the Th1/Th2 response or the
resistance of T cells to IL-10 found in RA patients. In contrast,
zymosan-induced arthritis was ameliorated in IL-6-deficient
mice but exacerbated in STAT1-deficient mice [74],
indicating that STAT1 is involved in the suppression of
inflammation in this model. In STAT1–/– mice, gene
expression of synovial SOCS1, but not that of SOCS3, was
markedly reduced in STAT1-deficient mice. The expression of
SOCS1 could be the underlying mechanism by which STAT1
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Figure 5
Regulation of lipopolysaccharide (LPS) signaling by STAT3 (signal
transduction and activators of transcription 3) and suppressor of
cytokine signaling 3 (SOCS3) in macrophages. SOCS3 strongly
suppresses STAT3 activated by IL-6/gp130 but not by IL-10, because
SOCS3 does not bind to the IL-10 receptor. STAT3 is shown to
suppress LPS signaling through STAT3, but the molecular mechanism
of this process has not been clarified.107
controls joint inflammation. The important role of SOCS1 in
joint inflammation and arthritis will probably be defined by
conditional gene knockout.
SOCS1 has so far been shown to be deeply involved in
hepatitis in humans. We found that SOCS1 gene silencing
by DNA methylation is frequently observed in hepatitis
induced by HCV infection [75], and SOCS1 gene
methylation was well correlated with the severity of liver
fibrosis, suggesting that decreasing SOCS1 gene expression
by DNA methylation promotes liver inflammation.
SOCS3 and inflammatory diseases
There is accumulating evidence that SOCS3 could suppress
inflammatory reactions in pathological situations in which IL-
6-related cytokines have important progressive functions.
This is because SOCS3 is a relatively specific inhibitor of
gp130 as described above. STAT3 activation and high
SOCS3 expression levels have been found in epithelial and
lamina propria cells in the colon of IBD (inflammatory bowel
disease) model mice, as well as in human ulcerative colitis
and patients with Crohn’s disease [76], and in synovial
fibroblasts of patients with RA [77]. In a dextran sulfate
sodium-induced mouse colitis model, a time-course
experiment indicated that STAT3 activation was 1 day ahead
of SOCS3 induction; STAT3 activation became apparent
during days 3 to 5 and decreased thereafter, whereas
SOCS3 expression was induced at day 5 and maintained
high levels thereafter. In murine models of inflammatory
synovitis, STAT3 phosphorylation preceded SOCS3
expression, which is consistent with the idea that SOCS3 is
part of the STAT3 negative-feedback loop [76]. We have
shown that overexpression of SOCS3 by adenoviral gene
transfer could prevent the development of experimental
arthritis [77]. The IL-6/STAT3 pathway therefore promotes
the progression of the chronic status of diseases by
contributing to cytokine and growth factor production, tissue
hyperplasia, synovial fibroblast proliferation, fibrosis and
osteoclast activation. On the basis of the evidence that
forced expression of SOCS3 can inhibit IL-6-mediated
STAT3 activation, we propose that SOCS3 is a negative
regulator of inflammatory diseases in synovial fibroblasts,
especially in those in which IL-6 levels are very high. A mouse
line of mutated gp130 in which the SHP-2/SOCS3-binding
site was disrupted developed a RA-like joint disease with
increased production of Th1-type cytokines and
immunoglobulins of the IgG2a and IgG2b classes [78]. In
another case, gastrointestinal inflammation and adenoma
were observed in similar mutant mice [79]. SOCS3 is
therefore also critical in the development of chronic
inflammatory disease. These studies reinforce the idea that
cytokines operating through gp130 are probably important in
activating RA synovial fibroblasts. Modulation of the
gp130–JAK–STAT pathway is therefore a reasonable
strategy for the development of new anti-inflammatory drugs.
Specific JAK kinase inhibitors might have a therapeutic role in
treating this and other disorders of the immune system,
especially if toxicity does not preclude their use.
In contrast, the enhanced action of SOCS3 may promote
allergic responses, because a recent analysis indicated that
transgenic SOCS3 expression in T cells inhibits Th1
development and promotes Th2 development [80]. Indeed,
that report also describes that increased SOCS3 expression
in T cells is correlated with the severity of human allergic
diseases such as asthma and atopic dermatitis. Modulation of
SOCS3 levels in T cells could be useful in regulating the
Th1/Th2 balance for the treatment of autoimmune
inflammatory diseases.
SOCS and human cancer
Anti-tumor activity of SOCS1 has been reported by several
groups. SOCS1 may inhibit the development and/or
progression of hepatocellular carcinoma (HCC), because
SOCS1 expression is significantly reduced in HCC cells; this
can be explained by the inactivation of the SOCS1 promoter
due to hypermethylation of CpG islands [81,82]. Yang and
colleagues [83] investigated the promoter methylation status
of major tumor suppressor genes including SOCS1, GSTP
(pi-class glutathione S-transferase), APC (adenomatous
polyposis coli), E-cadherin, RAR (retinoic acid receptor)-β,
p14, p15, p16 and p73 in 51 cases of HCC. Among these,
SOCS1 was the most frequently methylated (65%).
Methylation of SOCS1, APC and p15 was more frequently
seen in hepatitis C virus-positive HCC than in hepatitis C
virus/hepatitis B virus-negative HCC. These data suggest
that promoter hypermethylation of SOCS1 is an important
event in HCC development. In support of this, a recent
experiment has shown that SOCS1 heterozygous mice are
hypersensitive to dimethylnitrosamine-induced hepatocarcino-
genesis [75]. SOCS1 could be a novel anti-oncogene that
accelerates inflammation-induced carcinogenesis. DNA
hypermethylation of the SOCS1 gene is also found in several
solid tumors derived from the colon, stomach, ovary, lung and
breast; however, the frequencies in these tumors are not as
high as in HCC [84–91].
In addition, SOCS1 may inhibit the progression of
hematopoietic malignancies, because SOCS1 in vivo is
preferentially expressed in lymphoid organs. Recent reports
have indicated that reduced expression and DNA methylation
of SOCS1 are frequently found in myeloma and leukemia
cells [92,93]. Interestingly, biallelic mutation in the SOCS box
of the SOCS1 gene was found in 9 of 20 primary mediastinal
B cell lymphoma cells. These mutations probably result in
impaired JAK2 degradation and sustained JAK2 activation
[94]. In most cases, SOCS1 overexpression in cell lines
could inhibit tumor cell proliferation; SOCS1 could therefore
be an important target of anti-tumor therapy.
Like SOCS1, SOCS3 may also be involved in the
development and progression of malignancies. In chronic
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myelogenous leukemia cells, especially in cells in blast crisis
and T cell lymphoma, SOCS3 is expressed constitutively and
may confer resistance to IFN therapy [95,96]. In contrast,
silenced expression of SOCS3 due to hypermethylation has
been observed in human lung cancers and may be
associated with the progression of cancer cells [97].
Therapeutic application
A next important step of the study of SOCS is a clinical
application. Although it is too early to discuss its application
to humans, several interesting trials in vitro and in vivo are
under way. A group in the University of Florida developed a
tyrosine kinase inhibitor peptide, Tkip, that is a mimetic of
SOCS1 [98]. This 12-mer peptide interacts specifically with
the autophosphorylation site of JAK2 and inhibits IFN-γ
signaling. The peptide also suppressed the proliferation of
prostate cancer cell lines in which STAT3 is constitutively
activated [99]. Further characterization of JAK inhibition by
SOCS1-KIR and Tkip peptide may uncover a novel
mechanism to suppress the action of a specific cytokine.
Overexpression of SOCS3 by adenovirus can prevent mouse
RA models [77]. The generation of SOCS proteins carrying
membrane-permeable peptide by genetic engineering might
be another way to introduce JAK inhibitor into specific cells.
The reduction of SOCS expression is also a therapeutic
target. siRNA technology made the reduction of SOCS1
expression in DCs possible, and also improved anti-tumor
immunity [69]. A decrease in SOCS1 and SOCS3 by
antisense RNA treatment in obese diabetic mice improved
insulin sensitivity and ameliorated hepatic steatosis and
hypertriglyceridemia [100]. These studies are encouraging for
controlling cytokine-related pathological conditions by
mimicking or modulating SOCS proteins.
Conclusion
SOCS proteins are regulators of cytokine signal transduction
and are essential to normal immune physiology, but they also
seem to contribute to the development of immunological
disorders including inflammatory diseases. Recently
accumulated evidence regarding the balance of positive and
negative pathways is important for a better understanding of
immune systems, and this acquired knowledge will provide
new insights that will assist the development of novel thera-
peutic strategies for both immunological diseases and cancer.
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